Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome

Abstract : Background: Chromosome 4q loss of heterozygosity (LOH) is frequently observed in high-grade serous ovarian carcinoma (HGSOC). However, this LOH has not been clearly associated with the inactivation of any tumor suppressor gene(s). As the tumor suppressor gene PTPN13 is located on chromosome 4q21, we investigated its expression in HGSOC. Methods: PTPN13 protein expression was investigated by immunohistochemistry (IHC) in normal ovary epithelium and in 30 HGSOC samples, whereas PTPN13 mRNA expression was quantified by RT-PCR in another independent cohort of 28 HGSOC samples. Patients in both cohorts were followed for more than 8.5 years. Results: PTPN13 protein expression was lower in one third of HGSOC samples compared with normal ovary epithelium. In both cohorts, high PTPN13 expression level (mRNA or protein) in the tumor was associated with favorable outcome and significantly longer survival (HR=0.27; p=0.0087 and HR=0.42; p=0.03, respectively). Conclusion: This study demonstrates, for the first time, that high PTPN13 expression level is a prognostic indicator of favorable outcome in patients with HGSOC. This finding, in conjunction with our previous mechanistic studies, suggests that PTPN13 loss, possibly by 4q LOH, enhances HGSOC aggressiveness and highlight the interest of studying PTPN13 signaling in HGSOC to identify new potential therapeutic targets.
Liste complète des métadonnées
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : vendredi 11 octobre 2019 - 15:01:16
Dernière modification le : mercredi 20 novembre 2019 - 09:44:06

Lien texte intégral



Véronique D’hondt, Magalie Lacroix-Triki, Marta Jarlier, Florence Boissière-Michot, Carole Puech, et al.. High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome. Oncotarget, Impact journals, 2017, 8 (56), ⟨10.18632/oncotarget.21175⟩. ⟨hal-02313763⟩



Consultations de la notice